Exhibit 99.1 Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210 for treatment of chronic rhinosinusitis (CRS) – – Financing announced in June 2025 extends cash runway into 3Q 2026 – WATERTOWN, Mass., August 12, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasda ...